The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Open accessAbstract
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a first-in-class fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) inhibitor that suppresses PD-1 activity through selectively targeting and blocking the interaction between ligands (PD-L1 and PD-L2) and PD-1 receptor [35].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [35]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,000
Sheffield, B. S., Fulton, R. S., Kalloger, S. E., Milne, K., Geller, G. S., Jones, M. R., Jacquemont, C. F., Zachara, S., Stutheit-Zhao, E. Y., Pleasance, E., et al. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155416665338 · Cited by 33
Abdel-Rahman, O. M. (2017) · The Clinical Respiratory Journal · doi:10.1111/crj.12742 · Cited by 33
Roles for the FCRL6 Immunoreceptor in Tumor Immunology
Davis, R. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575175 · Cited by 33
Bae, J.-H., Baek, Y., Lee, J. E., Song, I., Lee, J.-H., & Shin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602365 · Cited by 36
Lim, J. S. J., & Soo, R. A. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816661091 · Cited by 33
Grizzi, G., Caccese, M., Γκουντάκος, Α., Carbognin, L., Tortora, G., Bria, E., & Pilotto, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1393333 · Cited by 33
Zhao, H., Yin, X., Wang, L., Liu, K., Liu, W., Bo, L., & Wang, L. (2023) · Scientific Data · doi:10.1038/s41597-023-02032-2 · Cited by 38
Saleh, T., Cuttino, L. W., & Gewirtz, D. A. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.012 · Cited by 32
A Perspective of Immunotherapy for Prostate Cancer
Silvestri, I., Cattarino, S., Giantulli, S., Nazzari, C., Collalti, G., & Sciarra, A. (2016) · Cancers · doi:10.3390/cancers8070064 · Cited by 32
Kohlhapp, F. J., Huelsmann, E. J., Lacek, A. T., Schenkel, J. M., Lusciks, J., Broucek, J. R., Goldufsky, J. W., Hughes, T. M., Zayas, J. P., Dolubizno, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.068 · Cited by 33
Durvalumab for the treatment of non-small cell lung cancer
Mezquita, L., & Planchard, D. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1494575 · Cited by 34
Self-citationWang, S., Hu, C., Xie, F., & Liu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s235714 · Cited by 32
Chimeric antigen receptor T‐cell therapy toxicities
Greenbaum, U., Kebriaei, P., Srour, S. A., Olson, A. L., Bashir, Q., Neelapu, S. S., Rezvani, K., & Shpall, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14403 · Cited by 32
Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
Kanjanapan, Y., & Yip, D. (2020) · Cancer Medicine · doi:10.1002/cam4.3532 · Cited by 32
Roudi, R., D’Angelo, A., Sirico, M., & Sobhani, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108322 · Cited by 31
Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
El-Osta, H. E., Shahid, K., Mills, G. M., & Peddi, P. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s111209 · Cited by 32
Mori, S., Motoi, N., Ninomiya, H., Matsuura, Y., Nakao, M., Mun, M., Okumura, S., Nishio, M., Morikawa, T., & Ishikawa, Y. (2016) · Pathology International · doi:10.1111/pin.12489 · Cited by 31
The 100 top-cited studies in cancer immunotherapy
Zhang, Y., Quan, L., & Du, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1623234 · Cited by 31
Çalık, İ., Çalık, M., Turken, G., Özercan, İ. H., Dağlı, A. F., Artaş, G., & Sarıkaya, B. (2019) · Medicina · doi:10.3390/medicina55110723 · Cited by 31
Imai, H., Wasamoto, S., Yamaguchi, O., Suzuki, K., Sugiyama, T., Uchino, J., Minemura, H., Osaki, T., Ishii, H., Umeda, Y., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03072-1 · Cited by 31
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 31
Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
Burns, E. A., Muhsen, I. N., Anand, K., Xu, J., Umoru, G., Arain, A., & Abdelrahim, M. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000358 · Cited by 31
Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
Goh, K. Y., Cheng, T. Y. D., Tham, S. C., & Lim, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020508 · Cited by 31
Nivolumab for treating non-small cell lung cancer
Guibert, N. M., & Mazières, J. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1114097 · Cited by 31
Self-citationMeniawy, T. M., Lake, R., McDonnell, A. M., Millward, M., & Nowak, A. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.006 · Cited by 31
Weir, G. M., Hrytsenko, О., Quinton, T., Berinstein, N. L., Stanford, M. M., & Mansour, M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0169-2 · Cited by 31
Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
Bourke, J., O'Sullivan, M. D., & Khattak, M. A. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00586 · Cited by 31
Clinical features, treatment, and outcome of nivolumab-induced cholangitis
He, Y., Fan, Z., Sun, W., Ouyang, L., & Wang, C. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2402338 · Cited by 30
Sgambato, A., Casaluce, F., & Gridelli, C. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1294157 · Cited by 30
Steuer, C. E., Griffith, C. C., Nannapaneni, S., Patel, M. R., Liu, Y., Magliocca, K. R., El‐Deiry, M. W., Cohen, C., Owonikoko, T. K., Shin, D. M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0504 · Cited by 30
Li, Y., Yu, J., Liu, Z., Yang, H., Tang, J., & Chen, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205138 · Cited by 30
Lal, J. C., Brown, S.-A. N., Collier, P. H., & Cheng, F. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00106-x · Cited by 31
Xu, Z., Hao, X., Yang, K., Wang, Q., Wang, J., Lin, L., Teng, F., Li, J., & Xing, P. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03901-2 · Cited by 30
Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Liu, D., Gao, S., Zhai, Y., Yang, X., & Zhai, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121527 · Cited by 30
Naidoo, J., Vansteenkiste, J., Finn, C. F., Özgüroğlu, M., Murakami, S., Hui, R., Quantin, X., Broadhurst, H., Newton, M., Thiyagarajah, P., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.003 · Cited by 30
Self-citationCombinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back
Chentoufi, A. A., Dhanushkodi, N. R., Srivastava, R., Prakash, S., Coulon, P.-G. A., Zayou, L., Vahed, H., Chentoufi, H. A., Hormi-Carver, K. K., & BenMohamed, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849515 · Cited by 31
Diamantopoulos, P. T., Gaggadi, M., Kassi, E. N., Benopoulou, Ο., Anastasopoulou, A. N., & Gogas, H. J. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000355 · Cited by 30
Yoon, B. W., Chang, B., & Lee, S. H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s271011 · Cited by 30
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
Drug-Induced Myopathies: A Comprehensive Review and Update
Miernik, S., Matusiewicz, A., & Olesińska, M. (2024) · Biomedicines · doi:10.3390/biomedicines12050987 · Cited by 29
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29
Iafolla, M. A. J., & Juergens, R. A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00067 · Cited by 29
Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations
Wang, G. X., Guo, L. Q., Gainor, J. F., & Fintelmann, F. J. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.16.17770 · Cited by 29
Retrospective study of nivolumab for patients with recurrent high grade gliomas
Mantica, M., Pritchard, A., Lieberman, F. S., & Drappatz, J. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2907-4 · Cited by 29
Sawada, K., Shonaka, T., Nishikawa, Y., Hasegawa, K., Hayashi, H., Hasebe, T., Nakajima, S., Ikuta, K., Fujiya, M., Furukawa, H., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2330-18 · Cited by 29
Novel Delivery Systems for Checkpoint Inhibitors
Lamichhane, P., Deshmukh, R. R., Brown, J. K., Jakubski, S., Parajuli, P., Nolan, T. A., Raja, D. S., Badawy, M., Yoon, T., Zmiyiwsky, M., et al. (2019) · Medicines · doi:10.3390/medicines6030074 · Cited by 29
Ocular side effects of checkpoint inhibitors
Alba‐Linero, C., & Alba, E. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.01.001 · Cited by 29
Kadokawa, Y., Takagi, M., Yoshida, T., Tatsumi, A., Fujita, K., Inoue, T., Ohe, S., Nakai, Y., Yamamoto, S., Otsuka, T., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2227 · Cited by 29
Zhai, C., Zhang, X., Ren, L., You, L., Pan, Q., Pan, H., & Han, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.619010 · Cited by 29
Wang, B., Guo, H., Xu, H., Yu, H., Chen, Y., & Zhao, G. (2021) · Cells · doi:10.3390/cells10102620 · Cited by 29
AllergoOncology: Role of immune cells and immune proteins
Gioacchino, M. D., Valle, L. D., Allegra, A., Pioggia, G., & Gangemi, S. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12133 · Cited by 30
Li, X., Zhou, X., Liu, J., Zhang, J., Feng, Y., Wang, F., He, Y., Wan, A., Filipczak, N., Yalamarty, S. S. K., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01123 · Cited by 30
Wang, Y., Li, C., Wang, Z., Wang, Z., Wu, R., Wu, Y., Song, Y., & Liu, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02580-1 · Cited by 29
Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
Grenda, A., Iwan, E., Krawczyk, P. A., Frąk, M., Chmielewska, I., Bomba, A., Giza, A., Rolska-Kopińska, A., Szczyrek, M., Kieszko, R., et al. (2022) · Cancers · doi:10.3390/cancers14246250 · Cited by 29
Recent developments in the use of immunotherapy in non-small cell lung cancer
Santarpía, M., Giovannetti, E., Rolfo, C. D., Karachaliou, N., González‐Cao, M., Altavilla, G., & Rosell, R. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1182866 · Cited by 28
Takebayashi, K., Ujiie, A., Kubo, M., Furukawa, S., Yamauchi, M., Shinozaki, H., Suzuki, T., Naruse, R., Hara, K., Tsuchiya, T., et al. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3257w · Cited by 28
Giraldo, N. A., Peske, J. D., Sautès‐Fridman, C., & Fridman, W. H. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-02517-1 · Cited by 28
Spagnolo, F., Boutros, A., Cecchi, F., Croce, E., Tanda, E. T., & Queirolo, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08165-0 · Cited by 31
Ding, Z., Meng, G.-X., Xue, J.-S., Yan, L., Liu, H., Yan, Y., Chen, Z., Hong, J., Wang, D., Dong, Z., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04133-8 · Cited by 28
Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis
Cosci, I., Grande, G., Nisio, A. D., Rocca, M. S., Fiore, P. D., Benna, C., D, S. M. M., & Ferlin, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010599 · Cited by 28
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28
Zhang, Y., Mudgal, P., Wang, L., Wu, H., Huang, N., Alexander, P. B., Gao, Z., Ji, N., & Li, Q.-J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1749476 · Cited by 28
Lin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Yadav, R., Khatkar, R., Yap, K. C.-Y., Kang, C., Lyu, J., SINGH, R. K., Mandal, S., Mohanta, A., Lam, H. Y., Okina, E., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02182-1 · Cited by 29
Li, J., Chen, Y., Shi, X., Le, X., Feng, F., Chen, J., Zhou, C., Chen, Y., Wen, S., Zeng, H., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.117 · Cited by 27
Sui, J.-D., Wang, Y., Wan, Y., & Wu, Y. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s167077 · Cited by 27
New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
Barquín, A., Molina‐Cerrillo, J., Garrido, P., Garcia-Palos, D., Carrato, A., & Alonso‐Gordoa, T. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.05.020 · Cited by 31
Research progress in immune checkpoint inhibitors for lung cancer in China
Gan, J., Huang, Y., Fang, W., & Zhang, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211029826 · Cited by 27
Sicca syndrome associated with immune checkpoint inhibitor therapy
Harris, J. A., Huang, K. B., Miloslavsky, E. M., & Hanna, G. J. (2021) · Oral Diseases · doi:10.1111/odi.14000 · Cited by 27
Webb, E. R., Moreno-Vicente, J., Easton, A., Lanati, S., Taylor, M., James, S., Williams, E. L., English, V., Penfold, C., Beers, S. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104995 · Cited by 27
Current and promising treatment strategies in glioma
Śledzińska, P., Bebyn, M. G., Furtak, J., Koper, A., & Koper, K. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0060 · Cited by 28
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC
Dercle, L., Fronheiser, M. P., Rizvi, N. A., Hellmann, M. D., Maier, S., Hayes, W., Yang, H., Guo, P., Fojo, T., Schwartz, L. H., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.12.019 · Cited by 27
Self-citationZhang, Y., Tian, Y., Zheng, L., Sun, X., Zhao, Z., Zheng, Y., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1103927 · Cited by 27
Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2
Wu, Z., Cao, Z., Yao, H., Yan, X., Xu, W., Zhang, M., Jiao, Z., Zhang, Z., Chen, J., Liu, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112693 · Cited by 27
Bandini, S., Ulivi, P., & Rossi, T. (2024) · Cells · doi:10.3390/cells13040337 · Cited by 27
New targeted treatments for non-small-cell lung cancer – role of nivolumab
Baas, P., Muller, M., van den Heuvel, M. M., & Zago, G. (2016) · Biologics · doi:10.2147/btt.s87878 · Cited by 28
Pluvy, J., Brosseau, S., Naltet, C., Opsomer, M.-A., Cazes, A., Danel, C. J., Khalil, A., Zalcman, G., & Gounant, V. (2017) · European Respiratory Journal · doi:10.1183/13993003.00310-2017 · Cited by 27
Self-citationXu, W., Zhang, X., Hu, X., Zhiyi, C., & Huang, P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.017 · Cited by 27
Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0492-9 · Cited by 27
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, E., Sgambato, A., Chiara, G. D., Casaluce, F., Losanno, T., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133289 · Cited by 26
Alexander, G. S., Palmer, J. D., Tuluc, M., Lin, J., Dicker, A. P., Bar‐Ad, V., Harshyne, L. A., Louie, J., Shaw, C. M., Hooper, D. C., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0328-4 · Cited by 26
Chou, S., Zhao, C. Y., Hwang, S. J. E., & Fernández‐Peñas, P. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.13013 · Cited by 26
A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy
Lu, Z., Zhang, Y., Wang, Y., Tan, G., Huang, F., Cao, R. Y., He, N., & Zhang, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.029 · Cited by 26
Kim, D. (2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.03.28 · Cited by 26
Programmed death 1 immune checkpoint inhibitors.
Trivedi, M. S., Hoffner, B., Winkelmann, J. L., Abbott, M., Hamid, O., & Carvajal, R. D. (2015) · PubMed · Cited by 26
Neoepitopes-based vaccines: challenges and perspectives
Alcazer, V., Bonaventura, P., Tonon, L., Valsesia‐Wittmann, S., Caux, C., & Depil, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.011 · Cited by 27
PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Bagley, S. J., Bauml, J. M., & Langer, C. J. (2015) · PubMed · Cited by 25
Genetic alteration profiling of patients with resected squamous cell lung carcinomas
Tao, D., Han, X., Zhang, N., Lin, D., Wu, D., Zhu, X., Song, W., & Shi, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9096 · Cited by 25
Sheng, Z., Zhu, X., Sun, Y., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18406 · Cited by 25
Pour, S. R., de Coaña, Y. P., Demorentin, X. M., Melief, J., Thimma, M., Wolodarski, M., Gómez-Cabrero, D., Hansson, J., Kiessling, R. W., & Tegner, J. N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002171 · Cited by 25
Yang, H.-M., Zhu, J., Xiao, R., Liu, Y., Yu, F., Cai, L., Qiu, M., & He, F. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03030-2 · Cited by 25
Raikwar, S., Jain, A., Saraf, S., Bidla, P. D., Panda, P. K., Tiwari, A., Verma, A., & Jain, S. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2044785 · Cited by 25
Imaging assessment of toxicity related to immune checkpoint inhibitors
Berz, A. M., Boughdad, S., Violi, N. V., Digklia, A., Dromain, C., Dunet, V., & Durán, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133207 · Cited by 26
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Bluthgen, M. V., & Besse, B. (2015) · European Respiratory Review · doi:10.1183/16000617.00002115 · Cited by 25
Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem
Spranger, S. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.008 · Cited by 25
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
Zhang, Y., Sun, Z., Mao, X., Wu, H., Luo, F., Wu, X., Zhou, L., Qin, J., Zhao, L., & Bai, C. (2017) · Oncotarget · doi:10.18632/oncotarget.20241 · Cited by 25
Takashima, Y., Sakakibara‐Konishi, J., Hatanaka, Y., Hatanaka, K. C., Ohhara, Y., Oizumi, S., Hida, Y., Kaga, K., Kinoshita, I., Dosaka‐Akita, H., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.02.004 · Cited by 25
The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma
Wu, S., Yang, W., Zhang, H., Ren, Y., Fang, Z., Yuan, C., & Yao, Z. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819869949 · Cited by 25
Liang, H., Xu, Y., Chen, M., Zhong, W., Wang, M., & Zhao, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13367 · Cited by 25
Zhao, X., Kassaye, B., Wangmo, D., Lou, E., & Subramanian, S. (2020) · iScience · doi:10.1016/j.isci.2020.101056 · Cited by 27
Metadata
- Authors
- Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Gustave Roussy (FR)
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Azienda Ospedaliera S.Maria (IT)
- Hôpital Civil, Strasbourg (FR)
- The Ohio State University Wexner Medical Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Mount Sinai Beth Israel (US)
- Lehigh Valley Hospital (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- University Hospital Cologne (DE)
- Hospices Civils de Lyon (FR)
- Ospedale di Livorno (IT)
- University Hospitals of Cleveland (US)
- Providence Portland Medical Center (US)
- German Center for Lung Research (DE)
- Princeton University (US)
- Emory University (US)
- Corresponding author
- Rizvi, Naiyer A
- ORCID
- Rizvi, Naiyer A
- Mazières, Julien
- Planchard, David
- Stinchcombe, Thomas E
- Dy, Grace K
- Antonia, Scott J
- Horn, Leora
- Mennecier, Bertrand
- Otterson, Gregory A
- Campos, Luis T
- Gandara, David R
- Levy, Benjamin P
- Nair, Suresh G
- Zalcman, Gérard
- Wolf, Jürgen
- Cappuzzo, Federico
- Chouaid, Christos
- Dowlati, Afshin
- Sanborn, Rachel
- Huber, Rudolf M
- Ramalingam, Suresh S
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 257-265
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5726228
- OpenAlex
- W2106511606
- Cited by
- 1,415
- References
- 36
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
- FWCI
- 108.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
- MeSH terms
- Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
